Granulocyte Functions: Patient (Before and After BMT), Donor, and Normal Control
| . | Patient . | Heterozygous Donor . | Normal Control . | |
|---|---|---|---|---|
| Before BMT . | After BMT . | |||
| NBT test (% positivity) | ||||
| PMA | 0 | 55.00 | 55.00 | 99.00 |
| OPZ | 0 | 62.00 | 60.00 | 100.00 |
| Cytochrome-b spectrum (pmol/106 granulocytes) | 0 | 5.90 | 4.70 | 6.50 |
| Superoxide production (nmol/106 granulocytes/min) | ||||
| PMA | 0 | 10.74 | 5.86 | 14.65 |
| fMLP | 0 | 12.46 | 9.34 | 17.76 |
| . | Patient . | Heterozygous Donor . | Normal Control . | |
|---|---|---|---|---|
| Before BMT . | After BMT . | |||
| NBT test (% positivity) | ||||
| PMA | 0 | 55.00 | 55.00 | 99.00 |
| OPZ | 0 | 62.00 | 60.00 | 100.00 |
| Cytochrome-b spectrum (pmol/106 granulocytes) | 0 | 5.90 | 4.70 | 6.50 |
| Superoxide production (nmol/106 granulocytes/min) | ||||
| PMA | 0 | 10.74 | 5.86 | 14.65 |
| fMLP | 0 | 12.46 | 9.34 | 17.76 |
Abbreviations: BMT, bone-marrow transplantation; NBT, nitroblue tetrazolium; PMA, phorbol-myristate-acetate; OPZ, opsonized zymosan particles; fMLP, N-formyl-methionyl-leucyl-phenylalanine.